Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 230 participants.

Also called NCT07076056

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 230 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT07076056
Other papers using this trial's data
  • Efficacy and Safety of Fixed-Dose Combinations of Sitagliptin and Empagliflozin as Add-On to Metformin in Korean Patients With Type 2 Diabetes: A Randomised, Double-Blind, Multi-Centre, Placebo-Controlled, Phase III Trial Diabetes, obesity & metabolism, 2026-06 DOI, PubMed 41883295, PMC13146161 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07076056. Randomized; double masking; primary purpose treatment. Start 2022-10-27 (actual); primary completion 2023-12-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2
Intervention (Drug)
DW1026C1
Intervention (Drug)
DW1026C2
Intervention (Drug)
DW1026S
Lead sponsor
Daewon Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07076056
Content hash
109f7cfeee0d27d36444d4f81ed55c4a993d57f174b167ea8be3944d535a479b